MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-06-2025
Codexis Net Debt 2011-2025 | CDXS
Net Debt can be roughly defined as financial liabilities that an entity classifies in the financing section together with the resources available to service those financial liabilities[1]
Net debt is the obligations that remain after deducting all assets and other liabilities from a company or individual. It represents the sum of debts that an organization or person must repay to their creditors or other parties.
Net debt can include various types of obligations such as loans, borrowings, lease liabilities, or credit card payments. It is important to note that net debt does not include current expenses or obligations such as payroll expenses or current bills.
Assessing net debt is an important financial indicator for evaluating the financial position of a company or individual. If net debt significantly exceeds assets, it may indicate financial difficulties and insolvency. In such cases, the company or individual may face difficulties in meeting their obligations and managing their finances.
Net debt can also be used to compare the financial stability of different companies. The lower the net debt relative to assets, the more stable and financially sound they are considered.
Overall, understanding net debt helps evaluate the financial soundness and ability of a company to meet their obligations. It is an important indicator that assists in making decisions about lending, investments, and financial management.
Annual Net Debt Codexis
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 12.5 M | -49.1 M | -62 M | -69.1 M | -148 M | -64.4 M | -52.6 M | -30.5 M | -18.8 M | -22.8 M | -26.5 M | -22.1 M | -32 M | -25.8 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 12.5 M | -148 M | -43.7 M |
References
- Pizzo, M., Moscariello, N., & Vinciguerra, R. (2015). Market Incentives and Regulators' Activity Shaping Financial Information: An Analysis of the Net Debt Disclosure in Italy. International Journal of Business and Management, 10(1), 1.
Net Debt of other stocks in the Biotechnology industry
| Issuer | Net Debt | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
163 M | - | 2.43 % | $ 254 M |  Germany |
 |
AlloVir
ALVR
|
-62.7 M | - | 4.14 % | $ 49.1 M |  USA |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
-402 M | - | - | $ 40.3 B | USA |
 |
Ascendis Pharma A/S
ASND
|
-195 M | $ 220.27 | 4.81 % | $ 5 B |  Danmark |
 |
Can-Fite BioPharma Ltd.
CANF
|
-3.5 M | $ 0.28 | -2.28 % | $ 609 M |  Israel |
 |
Alterity Therapeutics Limited
ATHE
|
-34.7 M | $ 3.3 | -3.51 % | $ 7.94 B |  Australia |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
-824 K | - | -1.52 % | $ 24.7 M | USA |
 |
Midatech Pharma plc
MTP
|
-6.17 M | - | -18.52 % | $ 27.3 M |  Britain |
 |
Aptorum Group Limited
APM
|
-2.77 M | $ 1.29 | -3.01 % | $ 7.03 M |  China |
 |
Biophytis SA
BPTS
|
-4.01 M | - | -13.47 % | $ 169 M |  France |
 |
Институт стволовых клеток человека
ISKJ
|
246 M | - | - | - |  Russia |
 |
ARCA biopharma
ABIO
|
-60.6 M | - | 1052.0 % | $ 415 M | USA |
 |
Arbutus Biopharma Corporation
ABUS
|
-107 M | $ 4.75 | 1.61 % | $ 788 M |  Canada |
 |
Aclaris Therapeutics
ACRS
|
-22 M | $ 3.26 | -3.12 % | $ 252 M | USA |
 |
Acasti Pharma
ACST
|
-27.4 M | - | 4.01 % | $ 150 M | Canada |
 |
Adaptimmune Therapeutics plc
ADAP
|
-119 M | - | -15.15 % | $ 60.3 M | Britain |
 |
Aeglea BioTherapeutics
AGLE
|
-30.2 M | - | - | $ 1.01 B | USA |
 |
Albireo Pharma
ALBO
|
-239 M | - | -0.23 % | $ 916 M | USA |
 |
Alpine Immune Sciences
ALPN
|
-63.9 M | - | - | $ 2.17 B | USA |
 |
Ampio Pharmaceuticals
AMPE
|
-12 M | - | -11.43 % | $ 502 K | USA |
 |
Amphastar Pharmaceuticals
AMPH
|
469 M | $ 25.27 | -2.43 % | $ 1.22 B | USA |
 |
Applied Molecular Transport
AMTI
|
-56.5 M | - | - | $ 10.1 M | USA |
 |
Anika Therapeutics
ANIK
|
-46 M | $ 9.57 | 0.84 % | $ 140 M | USA |
 |
BioNTech SE
BNTX
|
-973 M | $ 94.73 | -1.32 % | $ 27.2 B | Germany |
 |
Arena Pharmaceuticals
ARNA
|
-25.4 M | - | -6.81 % | $ 3.04 B | USA |
 |
Athersys
ATHX
|
-27.6 M | - | 3.77 % | $ 22.4 M | USA |
 |
Acer Therapeutics
ACER
|
-2.08 M | - | 2.71 % | $ 14 M | USA |
 |
Avenue Therapeutics
ATXI
|
-3.13 K | - | -52.27 % | $ 4.45 M | USA |
 |
AVROBIO
AVRO
|
-76.6 M | - | 1083.1 % | $ 745 M | USA |
 |
Axon Enterprise
AXON
|
-404 M | $ 566.18 | -2.56 % | $ 42.9 B | USA |
 |
Ayala Pharmaceuticals
AYLA
|
-657 K | - | - | $ 7.46 M | Israel |
 |
Aytu BioScience
AYTU
|
-19.9 M | $ 2.34 | 2.59 % | $ 14.7 M | USA |
 |
AstraZeneca PLC
AZN
|
9.86 B | $ 89.78 | -0.57 % | $ 96.9 B | Britain |
 |
Acorda Therapeutics
ACOR
|
114 M | - | -24.86 % | $ 820 K | USA |
 |
Brickell Biotech
BBI
|
-29.7 M | - | -5.38 % | $ 6.06 M | USA |
 |
Burford Capital Limited
BUR
|
-135 M | $ 9.09 | -0.55 % | $ 1.5 B | Britain |
 |
BeiGene, Ltd.
BGNE
|
-2.44 B | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
|
455 M | $ 11.54 | 0.87 % | $ 746 M | USA |
 |
Biogen
BIIB
|
4.01 B | $ 174.42 | 1.11 % | $ 25.4 B | USA |
 |
BioVie
BIVI
|
-17.2 M | $ 1.42 | -5.96 % | $ 2.1 M | USA |
 |
Abeona Therapeutics
ABEO
|
-9.07 M | $ 5.36 | -2.99 % | $ 115 M | USA |
 |
Dynavax Technologies Corporation
DVAX
|
-65.3 M | $ 10.85 | -0.14 % | $ 1.41 B | USA |
 |
ADiTx Therapeutics
ADTX
|
287 K | $ 2.3 | -3.0 % | $ 30.3 K | USA |
 |
Bellicum Pharmaceuticals
BLCM
|
-34.7 M | - | -9.72 % | $ 5.89 M | USA |
 |
Berkeley Lights
BLI
|
-60.5 M | - | -7.31 % | $ 87 M | USA |
 |
Advaxis
ADXS
|
3.42 M | - | -9.65 % | $ 45.9 M | USA |
 |
Завод ДИОД
DIOD
|
-48.6 M | - | - | - | Russia |
 |
Фармсинтез
LIFE
|
612 M | - | - | - | Russia |
 |
BioLineRx Ltd.
BLRX
|
-13.9 M | $ 3.17 | -1.86 % | $ 908 M | Israel |
 |
bluebird bio
BLUE
|
-163 M | - | - | $ 546 M | USA |